Progyny, Inc.
Financials
Valuation Metrics
Progyny, Inc.'s Market Cap is $2.26B. At end of 2025 it was $2.19B. Ranked #1894 of 3,114 in US market (top 61%), #695 of 1,469 on NASDAQ (top 47%), #115 of 203 in Health Care Equipment & Services (top 57%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.26B | US#1,894/3,114 Sec#115/203 |
| Revenue | $1.31B | US#1,708/3,114 Sec#107/203 |
| Net Income | $79M | US#1,718/3,114 Sec#86/203 |
| Total Assets | $716M | US#2,615/3,114 Sec#143/203 |
| Net Assets | $453M | US#2,285/3,114 Sec#118/203 |
| Employees | 835 | US#2,060/3,114 Sec#145/203 |
| Value | ||
| P/E | 28.71x | US#1,525/3,114 Sec#54/203 |
| P/B | 4.98x | US#2,215/3,114 Sec#132/203 |
| PEG | 0.60x | US#661/3,114 Sec#27/203 |
| P/S | 1.72x | US#1,150/3,114 Sec#75/203 |
| EV/EBITDA | 16.78x | US#1,668/3,114 Sec#66/203 |
| FCF Yield | 9.66% | US#606/3,114 Sec#19/203 |
| Profitability | ||
| ROE | 17.35% | US#736/3,114 Sec#32/203 |
| ROA | 10.98% | US#413/3,114 Sec#24/203 |
| Op. Margin | 8.55% | US#1,688/3,114 Sec#87/203 |
| Revenue Growth | 5.54% | US#1,710/3,114 Sec#125/203 |
| Earnings Growth | 48.02% | US#522/3,114 Sec#27/203 |
| Financial Health | ||
| Debt Ratio | 57.93% | US#655/3,114 Sec#73/203 |
| Total Debt | $27M | US#2,713/3,114 Sec#167/203 |
| FCF | $218M | US#1,340/3,114 Sec#78/203 |
| Cash | $153M | US#1,948/3,114 Sec#119/203 |
| Current Ratio | 2.14x | US#1,147/3,114 Sec#104/203 |
| Net Debt/EBITDA | -0.99x | US#286/3,114 Sec#22/203 |
| Performance | ||
| 1Y Return | 57.27% | US#434/3,114 Sec#42/203 |
| 1M Return | 16.63% | US#433/3,114 Sec#49/203 |
| From 52W High | -11.02% | US#913/3,114 Sec#80/203 |
| 1Y MDD | -42.65% | US#2,057/3,114 Sec#129/203 |
| Trading | ||
| Volume | 899,133 shares | US#1,906/3,114 Sec#126/203 |
| Trading Value | $26M | US#1,958/3,114 Sec#134/203 |
| Per Share | ||
| EPS | $1.02 | US#1,663/3,114 Sec#89/203 |
| BPS | $5.91 | US#2,194/3,114 Sec#138/203 |
Company Info
Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services, as well as pregnancy and postpartum, menopause and midlife, benefit and leave navigation, and parent and child wellbeing solutions. In addition, it provides assistance service program where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.